Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Short term Debt (2016 - 2025)

Historic Short term Debt for Ironwood Pharmaceuticals (IRWD) over the last 10 years, with Q3 2025 value amounting to $199.5 million.

  • Ironwood Pharmaceuticals' Short term Debt changed N/A to $199.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $199.5 million, marking a year-over-year change of. This contributed to the annual value of $199.6 million for FY2023, which is N/A changed from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Short term Debt of $199.5 million as of Q3 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Short term Debt peaked at $199.8 million during Q1 2024, and registered a low of $112.9 million during Q2 2021.
  • Moreover, its 5-year median value for Short term Debt was $199.2 million (2023), whereas its average is $166.2 million.